Tirzepatide, a dual agonist for GLP-1 and GIP receptors, effectively promotes weight loss and improves metabolic parameters by influencing insulin secretion, appetite regulation, and gastric emptying
Since tirzepatide has a half-life of approximately 5 days and its effects on gastric emptying persist throughout the dosing interval, the specific day matters less than maintaining consistent timing and monitoring your labs regularly
Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsuo, H., & Kangawa, K
And if thats the case, the algorithm has almost certainly noticed, and taken it as an invitation to send me moredespite all of the times Ive clicked not interested. To research this piece, I decided to see if Id actually be eligible to microdose the GLP-1 being promoted to me